Fractyl Health (GUTS) Stock Sees Fair Value Cut After Mixed Revita Analyst Reactions

The average fair value estimate for Fractyl Health shifted from about US$60.40 to roughly US$47.83, echoing the sharp reset in Street price targets from US$96 to US$39 and from US$48 to US$5. Analysts are weighing the six month Revita pivotal data against concerns about execution risk, real world uptake and how much of the weight regain benefit is already reflected in the stock. Read on to see how this evolving narrative could shape your view on Fractyl Health over the coming...